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Abstract
Human Natural Killer (NK) cells require at least two signals to trigger tumor cell lysis. Ab-
sence of ligands providing either signal 1 or 2 provides NK resistance. We manufactured a
lysate of a tumour cell line which provides signal 1 to resting NK cells without signal 2. The
tumor-primed NK cells (TpNK) lyse NK resistant Acute Myeloid Leukemia (AML) blasts ex-
pressing signal 2 ligands. We conducted a clinical trial to determine the toxicity of TpNK cell
infusions from haploidentical donors. 15 patients with high risk AML were screened, 13 en-
rolled and 7 patients treated. The remaining 6 either failed to respond to re-induction chemo-
therapy or the donor refused to undergo peripheral blood apheresis. The conditioning
consisted of fludarabine and total body irradiation. This was the first UK trial of a cell therapy
regulated as a medicine. The complexity of Good Clinical Practice compliance was under-
estimated and led to failures requiring retrospective independent data review. The lessons
learned are an important aspect of this report. There was no evidence of infusional toxicity.
Profound myelosuppression was seen in the majority (median neutrophil recovery day 55).
At six months follow-up, three patients treated in Complete Remission (CR) remained in re-
mission, one patient infused in Partial Remission had achieved CR1, two had relapsed and
one had died. One year post-treatment one patient remained in CR. Four patients remained
in CR after treatment for longer than their most recent previous CR. During the 2 year fol-
low-up six of seven patients died; median overall survival was 400 days post infusion
(range 141–910). This is the first clinical trial of an NK therapy in the absence of IL-2 or
other cytokine support. The HLA-mismatched NK cells survived and expanded in vivo with-
out on-going host immunosuppression and appeared to exert an anti-leukemia effect in 4/7
patients treated.
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Introduction
Acute Myeloid Leukemia (AML) is rarely cured by chemotherapy alone and even high dose
therapy with allogeneic transplantation is associated with poor overall survival in patients with
adverse prognostic factors as defined by cytogenetic, molecular and other markers. Further-
more, it is only available to those with suitably matched donors and is associated with unac-
ceptable toxicity in elderly patients or in patients with co-morbidities. Therefore, alternative
modalities are required which can potentially be applied in all age groups with minimal toxicity
and maximum clinical efficacy. In this context, different approaches using immunotherapy or
immunomodulation have been tried either as part of induction, during consolidation and less
often as maintenance in the treatment of AML.
NK cells play a significant role in the autologous immune response to solid tumors [1] and
haematological malignancies such as myeloma [2] and AML [3,4] but their use as adoptive im-
munotherapy has led rarely to success. In AML, where the malignant blast cells express high
levels of MHC class I antigens [5] which may inhibit autologous NK cell function, attention
has focussed on use of HLA-mismatched NK cells from haploidentical donors [6, 7, 8, 9]. How-
ever, resting human NK cells require two signals to initiate cytokine secretion and cytotoxicity
[10] and AML blasts frequently lack one or both of the cognate ligands. We identified an NK
priming mechanism which is independent of cytokines and is meditated by tumor cells, includ-
ing the leukemia cell line CTV-1 (DSMZ) [3]. This priming mechanism is meditated through
CD2 and is unique in that, unlike cytokine-mediated priming, tumor-primed NK cells retain
the primed state even after cryopreservation [11]. Moreover, the tumor-primed NK cells lyse a
wide range of NK-resistant tumors including breast and ovarian cancers [3], lymphomas and
prostate cancer [11] and primary myeloma cells [2]. The ability to use cryopreserved aliquots
of primed, donor NK cells is a fundamental advance in adoptive NK cell therapy as products
can be manufactured centrally, cryopreserved to allow confirmation of functional activity, test-
ed to ensure sterility before release and shipped under temperature-controlled conditions to
the patient’s bedside for administration. This allows compliance with the European Union, US
and Australian medicines regulations which designate these cells as medicines and thus require
robust quality control during manufacture and at the time of release.
We have developed a manufacturing process which complies with EU pharmaceutical Good
Manufacturing Practice (GMP) and US cGMP and which generates highly purified, dosed ali-
quots of allogeneic, primed NK cells from related haploidentical donors, which lyse NK-resis-
tant tumor cells. Here we present the data from the first clinical trial of these tumor-primed
NK cell suspensions as an investigational medicinal product (IMP).
Patients and Methods
Ethics statement
This trial was approved by the UKMedicines & Healthcare products Regulatory Agency and
by the institutional Royal Free Hospital NHS Trust Local Research Ethics Committee (EudracT
number: 2005-006087-62) and by the Clinical Trials Committee of the UK Leukaemia Lym-
phoma Research which was the principal funding body. All patients and their related HLA-mis-
matched NK cell donors gave written, informed consent.
The protocol for this trial and supporting TREND checklist are available as supporting in-
formation; see S1 Protocol and S1 TREND Checklist.
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Patient eligibility
A phase 1 dose escalation trial was planned for patients with acute myeloid leukemia (AML)
excluding APML. Patient eligibility criteria were as follows: 1) Age>60 years in partial remis-
sion (PR) after two courses of induction chemotherapy, or in second complete remission
(CR2) after reinduction chemotherapy; 2) Age>60 years with poor risk disease using standard
MRC criteria in CR or PR after two courses of chemotherapy; 3) age<60 years beyond CR2
who were not suitable for stem cell transplantation with conventional myeloablative or reduced
intensity conditioning regimens.
The NK cell donors were HLA-haploidentical blood relatives of patients, aged 18–65 years.
HLA typing was determined for patients and donors using high resolution molecular tech-
niques according to our standard hemopoietic stem cell transplant (HSCT) practice.
Patient Characteristics
Between July 2008 and January 2010, a total of 15 patients with high risk AML were screened;
two of whom failed to respond to re-induction chemotherapy and thus failed enrolment crite-
ria. Of the 13 patients enrolled four patients (median age 54 years, range, 22 to 76 years) died
of primary refractory/relapsing disease and one patient died of neutropenic sepsis during rein-
duction chemotherapy before any had received NK cell treatment. One patient was withdrawn
from the study as the donor refused to undergo peripheral blood apheresis (Fig 1).
Thus a total of seven patients finally proceeded to receive donor TpNK cell infusion. Char-
acteristics of the evaluable patients are summarized in Table 1. The median age at diagnosis
was 65 years (range, 49 to 73 years) and 67 years at treatment. The majority of patients were
male (71.4%). Four patients (57.1%) were beyond second-line chemotherapy and three (42.9%)
were beyond third-line chemotherapy for relapsing AML, where one patient had undergone
autologous hemopoietic stem cell transplantation (HSCT) and two (25%) allogeneic HSCT
from HLA matched donors.
The Karnofsky performance at treatment was 100% and no patients had co-morbidities.
However, one patient had type II diabetes mellitus, one patient suffered from chronic Hepatitis
C virus infection on antivirals (lamivudine) and one had undergone prostatectomy due to pros-
tate cancer 11 years prior to his diagnosis of leukemia.
The disease status at the time of the IMP infusion was as follows: Two patients (28.6%) were
in first complete remission (CR1) with poor risk disease, one patient (14.3%) in second (CR2),
three patients (42.9%) in third (CR3) and one patient was in first partial remission (PR1) with
fewer than 25% blasts in the marrow. The median duration of first complete remission period
for patients who were beyond first relapse was 689.5 days (range 210–1320 days), the median
duration of second complete remission period for those who were beyond second relapse was
270 days (range 240–419 days). Median follow up time was 433 days (range 148 to 1180 days).
Conditioning regimen and supportive care
The conditioning regimen for patients comprised of fludarabine 25mg/m2 for 5 days and Total
Body Irradiation (TBI) as a single dose of 2 Gy (Fig 2). However, the protocol was amended
after the first patient’s treatment due to prolonged cytopenia and the dose of fludarabine was
reduced to 3 days, while the TBI remained unchanged.
Anti-infective prophylaxis was initiated at commencement of the conditioning and con-
sisted of acyclovir 200mg bd and itraconazole 200mg iv as per institutional guidelines for pa-
tients undergoing HSCT.
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Fig 1. Trial enrollment summary.
doi:10.1371/journal.pone.0123416.g001
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Trial Protocol
After identification of suitability, patients were assessed and enrolled after informed consent.
This initiated HLA typing of the patient and one or more consenting, related donors. Where
more than one donor was available preference was given to those with HLA mismatch detect-
able by flow cytometry as described below. Presence or absence of predicted KIR ligand mis-
match was random.
The trial was a 3-stage dose escalation protocol (S1 Protocol) in which the first 5 patients
would each receive a single dose of 1x106 NK/kg patient body weight. In the absence of dose
limiting toxicity the next five patients would receive 5x106 NK/kg and the third cohort would
receive 1x107 NK/kg. In all cases the patients would receive<104 T cells/kg patient body weight
to prevent graft versus host disease (GvHD) and this was the primary release criterion for the
IMP. Treatment of all patients within a cohort was to be separated by at least 7 days.
Dose escalation required approval of the Data Safety Monitoring Committee and could only
occur a minimum of 1 month after infusion of the 5th patient of the lower dose cohort. After
treatment of the second patient in the first cohort the protocol was amended to allow a second
infusion of a single dose of 1x106 cells/kg in the event of relapse, but without additional
conditioning chemotherapy.
Donor apheresis and NK cell generation
All consenting donors underwent a 2 hour apheresis approximately 20 days prior to the infu-
sion and none of them experienced any complications. The median number of mononuclear
cells recovered was 117.3x108 of which 49.1x108 were CD56-ve/CD3+ve T cells and 10.05x108
Table 1. Patient Characteristics.
UPN sex Age at
diagnosis
(years)
Age at
treatment
(years)
Cytogenetics 1st line
chemotherapy
2nd line
chemotherapy
3rd line
chemotherapy
Allo
HSCT
CR 1
duration
(days)
CR2
duration
(days)
recent
CR
duration
pre- IMP
(days)
Disease
status at
treatment
CTI-
01
F 51 54 trisomy 21 DA/My, DA,
MACE, MidAC
FLAG, MACE,
BuCy, Auto
HSCT
HiDAC no 540 419 30 CR3
CTI-
03
M 71 72 N/A 5 azacytidine no PR1
CTI-
04
M 49 51 t(9;11) ADE×2, MACE ICE, BuCy
AlloHSCT
ICE yes 210 270 30 CR3
CTI-
07
M 71 71 Complex DA×2 no 60 CR1
CTI-
09
F 73 73 Trisomy 13 DA×1 no 47 CR1
CTI-
08
M 65 67 Normal DA×3,5
azacytidine
FLAG no 839 62 CR2
CTI-
11
M 56 61 Trisomy 9 DA×2,FluCy-
AlloHSCT
Rx (auditory
meatus MS)
HiDAC yes 1320 240 90 CR3
Abbreviations: UPN, unique patient number; DA, Daunorubicin + Cytosine Arabinoside; My, Mylotarg; ADE, Cytosine Arabinoside + Daunorubicin + Etoposide;
MACE, Amsacrine +Cytosine Arabinoside+Etoposide; MidAC, Mitoxantrone+Cytosine Arabinoside; FLAG, Fludarabine+ Cytosine Arabinoside+G-CCF; BuCy,
Busulfan+Cyclophosphamide; ICE, Ifosfamide+Cyclophosphamide+Etoposide; Rx, Radiotherapy; MS, Myeloid Sarcoma; HiDAC, High dose Cytosine
Arabinoside; HSCT, Haemopoietic Stem Cell Transplantation; CR, complete remission; PR, partial remission; IMP, A, not available/A, not available
doi:10.1371/journal.pone.0123416.t001
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were CD56+ve/CD3-ve NK cells. 6.27x108 were CD56+ve/CD3+ve NKT cells. The donor
mononuclear cells fractions were labelled with anti-CD56 paramagnetic microbeads (Miltenyi
Biotec UK, Ltd) and positively selected by CliniMACS (Miltenyi Biotech GMBH). The mean
purity of CD56+ cells was 97.17% of which over 80% were CD56+ve/CD3-ve NK cells. There
was a 3.5 log fold reduction in T cells and all products met the acceptance threshold of<1x104
T cells per Kg patient body weight.
The CD56+ fraction was incubated overnight in X-Vivo10 (BioWhittaker) with a lysate de-
rived from CTV-1 leukemia cells (DSMZ) grown to GMP-compliance in our own laboratories.
Briefly, CTV-1 cells maintained in X-Vivo10 supplemented with 5% human serum albumin
(Bio Products Laboratory, Elstree, UK) were transferred to 50ml Cryocyte bags (Miltenyi Bio-
tech, Ltd, Bisely, Surrey UK) and frozen overnight at -80°C. Cells were thawed rapidly at 37°C,
frozen again at -80°C and thawed for a second time in the presence of DNAse (Pulmozyme,
Roche, Welwyn Garden City UK). The resultant cell lysates were centrifuged at 2500 x “g”, re-
suspended in X-Vivo10 at an interpolated concentration of 2x107 CTV-1 /bag and transferred
to storage at -80°C after test aliquots had been removed. Batches of CTV-1 lysate were tested
for sterility, Mycoplasma and endotoxin as well as functional ability to prime resting, donor
NK cells in vitro. Batches passing the QC assays were released for use in GMP-compliant man-
ufacture of primed NK cells.
After overnight co-incubation of resting donor NK cells with CTV-1 lysate, the lysate was
removed by discontinuous density gradient separation and aliquots of NK cells were taken to
confirm NK priming in a functional assay. Patient-specific doses were cryopreserved in indi-
vidual aliquots in nitrogen vapour phase and formally released upon completion of sterility
and functional testing. Patient-specific products were dispensed for infusion upon completion
of the conditioning treatment and were thawed at the patient bedside for immediate
administration.
Patient immune monitoring
Anticoagulated and clotted peripheral blood samples from patients were taken pre-infusion
and at approximately 7, 14, 21, 28, 57, 90 and 180 days post infusion according to the trial pro-
tocol and patient assent. Additional samples were taken at later time points in long term sur-
viving patients. Bone marrow aspirates were taken as indicated for clinical management and
excess sample material was released for immune monitoring as described in the protocol
when available.
All samples were analysed for T and NK cell subsets and for expression of CD69 as an indi-
cator of in vivo cell activation. In patients with sufficient circulating NK cells samples were also
tested for the presence of circulating primed NK cells capable of in vitro lysis of NK resistant
RAJI cells without additional priming. In patients for whom an informative HLA-mismatch
Fig 2. Patient conditioning regimen.
doi:10.1371/journal.pone.0123416.g002
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could be detected by a specific anti-MHC class I monoclonal antibody samples were also tested
for microchimerism by flow cytometry to determine the proportion of donor cells within the
circulating CD56+/CD3- NK and the CD56-/CD3+ T cell pools. Briefly, a minimum of 106 pe-
ripheral blood mononuclear cells were labelled with anti-CD3 FITC, anti-CD56 APC and ei-
ther anti-HLA A2, or anti-HLA A24 or anti-HLA B7 conjugated to PE, depending upon the
specific mismatch between donor and recipient and analysed by flow cytometry. The analysis
was restricted to cases where the donor cells expressed the specific HLA type which was lacked
by the recipient, leading to detection of HLA-expressing donor cells in recipient samples. As
shown in Fig 3A and 3B, this flow cytometric assay was pre-validated by “spiking” experiments
to a sensitivity of 0.2% donor cells in recipient blood. Briefly, donor NK cells expressing a mis-
matched MHC class I allele for which a specific monoclonal antibody was available were spiked
into a suspension of recipient blood mononuclear cells at dilutions ranging from 1:20 to 1:200.
These donor cells were reliably detected with high reproducibility and a significant correlation
(coefficient of variance of<10%). The inverse situation where donor cells lacked a specific
HLA antigen which was present on recipient cells was not used due to high frequency of “false
positive” pre-infusion blood samples.
Results
Clinical Outcome
The first patient treated experienced prolonged pancytopenia after infusion of the TpNK dose
of 1x106/kg as discussed below in “Adverse Events and Toxicity”. This led to a protocol amend-
ment and a reduction in the intensity of the conditioning regimen for the remaining patients.
However, despite this, the following patient in cohort 1 suffered the same pancytopenia and
the DSMC decided that an additional patient must be treated at the starting dose of 1x106/kg,
making 6 in the first cohort, before a decision on dose escalation could be made. The 4th patient
treated also experienced profound and prolonged neutropenia and thrombocytopenia and it
was decided that the maximum tolerated dose had be achieved for this patient population and
with this conditioning regimen. Dose escalation was halted and all patients treated received a
dose of 1x106/kg TpNK.
At six months post IMP infusion, three patients treated in CR remained in remission phase
of disease (37.5%), two had relapsed and one had died. One patient who had not achieved CR
after conventional induction chemotherapy and was infused at PR1 had achieved CR1 after
50 days from the infusion, He remained in complete remission, relapsing 10 months later. A
protocol amendment allowed him to receive a second dose of primed NK cells from the same
donor on day +327 but without immunosuppressive conditioning chemotherapy. The HLA-
mismatched donor NK cells engrafted without lymphodepleting conditioning and despite
complete absence of immunosuppression. He never regained CR but remained stable for a fur-
ther +203 days after the 2nd infusion while in relapse.
At one year post treatment only one patient remained in disease remission, three more had
relapsed but no more deaths has occurred (Table 2). Four patients remained in CR after IMP
treatment for longer than their most recent previous CR. All patients finally relapsed. Median
time to relapse was 253.5 days post TpNK infusion (range, 58 to 845 days) and the median
overall survival was 468.5 days (range, 148 to 1180 days).
During the 2 year follow-up period, six out of seven trial patients (86%) (Fig 4) died as did
the single patient treated off-trial. The cause of death was AML relapse in five patients, intra-
cranial haemorrhage due to profound thrombocytopenia in one patient and septic shock in the
sixth. The median duration of survival after relapse was 174 days (range, 90 to 335 days).
Tumor-Primed NK Cells in AML - Phase I Trial
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Donor NK cell chimerism
Three of the seven treated patients (CTI-01, 03 and 04) received donor products which were
identifiable by flow cytometric chimerism assay. All three patients had detectable donor NK
cells in their peripheral blood and/or bone marrow at more than one time point post infusion
(Fig 3C, 3D and 3E). The maximum donor NK chimerism in peripheral blood after a single in-
fusion of 1x106 NK/kg ranged from 1.7% in patient 03 to 22.5% in patient 04. The highest
achieved in patient 02 being 9.4%. These were all in the absence of detectable donor T cells. Pa-
tient 03 received a second infusion after an approved protocol amendment, without additional
conditioning. He had attained a maximum peripheral blood NK chimera after the first infusion
of only 1.74% and showed an undetectable peripheral blood NK chimerism 7 and 14 days after
the second infusion. However, his disease remained controlled and at day +48 a bone marrow
aspirate showed an NK donor chimera of over 30% whilst donor T cells remained undetectable
(Fig 5). The donor NK cells all expressed the activation antigen CD69 (data not shown).
In vivo NK cell activation
Patients were monitored for the presence of activated NK and T cells before and at multiple
time points after infusion of the tumor primed NK cell product. Five of six evaluable patients
showed the presence of circulating primed NK cells as measured by their ability to lyse the NK-
Fig 3. Donor NK chimerism.Donor NK chimerism was measured by flow cytometry using monoclonal antibodies specific for an MHC Class I allele which
was restricted to the donor cells. Concomitant labeling with anti-CD3 and anti-CD56 allowed detection of donor T, NKT and NK cells in patients’ peripheral
blood and bone marrow. Preliminary experiments confirmed sensitivity (A) and specificity; indeed the method consistently underestimated the dosed
proportion of donor cells (B). Three evaluable patients showed consistent presence of low levels of donor NK cells (filled circles and solid line) in peripheral
blood (C, D, E). Patient 01 (C) and Patient 03 (D) showed absence of donor T cells (open triangles and dashed line). Patient 04 who suffered profound
marrow aplasia and required allogeneic stem cell rescue was the only one to have detectable donor T cells in repeated blood samples (E).
doi:10.1371/journal.pone.0123416.g003
Table 2. Response after Treatment.
UPN CR duration
post IMP(days)
disease status
day +100
disease status
day +170
disease status
+12 months
Overall survival
post- IMP (days) c
CTI-
01
845 3rd CR 3rd CR 3rd CR 1180†
CTI-
03
250a 1st CR 1st CR 1st relapse 530b †
CTI-
04
284 3rd CR 3rd CR 3rd relapse 504 †
CTI-
07
55 2ndrelapse Deceased deceased 148 days †
CTI-
09
141 1st CR 1st relapse 1st relapse 433 days †
CTI-
08
116 2nd CR 2nd relapse 2nd relapse 366 days †
CTI-
11
352 3rd CR 3rd CR 3rd relapse 414†
Abbreviations: IMP, Investigational Medical Product;
a complete remission was achieved 50 days after the IMP infusion
b the patient received 2nd IMP infusion upon relapse on day+327 and died 203 days after the
second infusion
c last follow-up on 01/02/2011
† deceased patients
doi:10.1371/journal.pone.0123416.t002
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resistant cell line RAJI in an in vitro killing assay. Six of seven evaluable patients showed an in-
crease in the proportion of activated NK cells in their circulation after infusion (Fig 6A). The
one patient (03) who did not show an expansion of circulating CD69+ NK cells was the only
individual who showed high endogenous activation of autologous NK cells (33.4% CD69+) im-
mediately following conditioning chemotherapy and prior to TBI. The presence of circulating
primed NK cells able to lyse RAJI cells coincided with the presence of CD69+ve NK cells in the
peripheral blood and was only apparent after infusion of primed donor NK (Fig 6A).
Adverse events and Toxicity
All seven treated patients were assessable for toxicity post infusion of IMP. All serious adverse
reactions (SAR) that were probably or definitely attributed to treatment are listed in Table 3.
The median duration of hospitalization post infusion was 31 days (range, 5 to 97 days). Both
the conditioning regimen as well as the IMP infusion was tolerated well as none of the patients
experienced any infusion related toxicity. None of the patients developed any evidence of
Fig 4. Clinical outcome. Duration of most recent previous CR (black blocks) or PR (white block) prior to ATIMP administration (white arrow) is shown
relative to the duration of CR post IMP infusion (gray blocks). Patients 01, 03, 04 and 11 all experienced a longer duration of remission post IMP infusion than
their previous CR which was not seen in the other patients.
doi:10.1371/journal.pone.0123416.g004
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GVHD in any organs, however, in the view of cytopenias, bone marrow specific GVHD cannot
be excluded.
Hematological toxicity as evidenced by profound myelosuppression was observed in 6 of 7
patients. According to the protocol aplastic anaemia was defined as unexpected neutrophils
count<0.5×109/l with Hb<8g/l and platelets<20×109 /l, for more than 28 days. The median
time interval to neutrophil recovery (defined as absolute granulocyte count>0.5 ×109/l) was
55 days (range, 19 to 101 days). Platelet recovery (defined as absolute platelet count>50×109/l)
was achieved only in four patients (50%) with a median time of 59 days (range, 31 to 114 days).
Two patients achieved absolute platelet count>25×109/l after a median period of 64 days
(range, 44 to 289 days) with platelet count never exceeding 50×109/l, while one patient remained
Fig 5. Detection of donor NK cells in bonemarrow. A single bone marrow aspirate taken from Patient 03 48 days after receipt of a second infusion of
primed donor NK cells showed absence of HLA-A24+ donor T cells (A and B). Donor NK cells (C) expressing HLA-A24 represented almost 1/3 of the total NK
cells in the bone marrow (D).
doi:10.1371/journal.pone.0123416.g005
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thrombocytopenic (<25×109/l) throughout the whole follow-up period. The two patients (04,
11) who experienced the longest duration of bone marrow suppression and grade 4 neutropenia
unresponsive to G-CSF had both previously undergone allogeneic hematopoietic stem cell trans-
plant as part of their routine treatment prior to this trial. Each of these patientsreceived CD34+
cell top up from their original HSCT donor after a median period of 74 days post IMP infusion.
This hematopoietic rescue was not within the trial protocol but resolved the neutropaenia in
both cases (Table 4).
The assessment of individual patient’s initial transfusion requirements was continued for a
median duration of 84 days (range, 11 to 170 days), and the median number of RBC and PLT
units transfused were 16 (range, 2 to 26) and 13 (range, 1 to 35) respectively. Six patients were
treated with G-CSF on attending physician’s preference.
Almost all of the patients developed at least one episode of neutropenic fever. All patients
were hospitalized for infections and two patients were admitted to the intensive treatment
Fig 6. Presence of activated NK cells in peripheral blood. All patients were monitored for the proportions
of resting and activated NK cells in their peripheral blood prior to and post primed allogeneic NK cell infusion.
NK cell activation in peripheral blood increased within the first two weeks of infusion and did not return to pre-
infusion levels until week 12 (A—data shown are mean +/- SD n = 7). A single patient (01) was consistently
monitored for the presence of activated NK cells in her peripheral blood which lysed NK-resistant Raji cells in
vitro at a fixed effector:target ratio of 5:1 (B—closed circles). The presence of functional primed NK cells
closely mirrored the presence of CD69+ NK cells (B—open squares).
doi:10.1371/journal.pone.0123416.g006
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unit (ITU) due to neutropenic sepsis. Among documented infections, five patients developed
pneumonia and three had septicaemia. Probable fungal infection was diagnosed in three out
of the five patients who developed pneumonia. Hepatic toxicity defined as elevated ALT
by>×2 ULN was noted in only one patient while two patients presented elevated urea and
creatinine and the values were normalized after a period of 140 days, 42 and 140 days after
infusion respectively.
Patient 04 was the third patient treated and the first to experience prolonged and severe
neutropenia after the reduction of the conditioning regimen. He was also the first patient who
had previously undergone an HLA-identical sibling donor peripheral blood stem cell trans-
plant. The tumor-primed NK cells he received were manufactured from a second, HLA-mis-
matched brother and, in response to his post treatment neutropenia, he received a CD34
selected top-up graft from his original matched sibling donor. At this time we tested a cryopre-
served sample of the batch of tumor-primed NK cells he had received for their ability to inhibit
in vitro myelopoiesis by the HLA-matched sibling CD34+ cells in colony forming assays.
A test vial of the investigational product used in this patient was thawed and tumor-primed
NK cells were pre-incubated at an effector:target ratio of 10:1 in vitro with CD34+ donor cells
for 4 hours and then the co-culture was resuspended in Methocult and cultured for a further
14 days before analysis of the colony formation. The growth of BFU-E, GFU-M and CFU-
Table 3. Severe Adverse Reactions (SAR).
SAR No. of Patients N = 7 %
Neutropenia 7 100
Neutropenic fever 7 100
Infection Pneumonia 5 71.4
Probable Fungal pneumonia 3 42.9
Virus infection 2 28.6
Neutropenic sepsis 5 71.4
ITU admission 2 28.6
Platelet reaction 1 14.3
Bone Marrow Suppression 7 100
Aplastic Anaemia 6 85.7
Elevated transaminases 1 14.3
Elevated U, Cr 2 28.6
Abbreviations: ITU, Intensive Care Unit
doi:10.1371/journal.pone.0123416.t003
Table 4. Neutropenias.
Patient Day Neutrophil <0.5 Day Neutrophil >0.5
CTI-01 +8 +59
CTI-03 +5 +40
CTI-04 +18 +101
CTI-07 +4 +19
CTI-09 +2 +51
CTI-08 +15 +43
CTI-11 +15 +93
Subjects in BOLD were prior recipients of allogeneic HSCT and received allogeneic CD34+ cell infusions
to resolve the grade 4 neutropenias.
doi:10.1371/journal.pone.0123416.t004
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GEMM was determined in cultures established with and without the TpNK IMP. As a positive
control for CFU inhibition, parallel cultures were established with CD3+ T cells from the same
donor.
As shown in Fig 7A, there was no detectable suppression of CFU-GM, CFU-GEMM or
BFU-E in the cultures pre-treated with HLA-mismatched sibling tumor-primed NK cells. In
contrast, the donor T cells substantially inhibited GFU-GM whilst the BFU-E and CFU-
GEMM were unaffected (Fig 7B). Analysis of microchimerism demonstrated that this patient
had an early transient expansion of donor T cells after TpNK infusion which was not seen in
other patients who were monitored (fFg. 7c).
KIR-ligand incompatibility
As shown in Table 5, only two patients received tumor-primed NK infusion in the face of pre-
dicted KIR incompatibility. Patient 03 received cells in the face of a predicted host versus
donor response and yet showed durable engraftment after both the first and second infusion
despite the presence of autologous NK cells at both times. Patient 04 received NK cells with a
predicted donor-versus-host reaction and was also the first patient to require Peripheral Blood
Stem Cell Transplantation (PBSCT) rescue (the second patient whose aplasia was rescued by
PBSCT had no predicted KIR mismatch).
Discussion
The purpose of this study was primarily to determine the feasibility and safety of haploidentical
NK cells following fludarabine and TBI conditioning in a cohort of patients with high risk
AML who were not eligible for curative standard allogeneic stem cell procedures or other
conventional modalities.
No infusional side effects were noted, however prolonged cytopenias occurred in all patients
and most severely in those who had received a previous allogeneic transplant and for whom
rescue with a CD34+ stem cell infusion was required from the original donor.
The cause of the aplasia remains obscure and it might be associated either with the toxicity
of the conditioning regimen and especially with the TBI, the NK cells or the combination of
both. In fact similar cytopenias have been observed in previous studies, however the regimens
were different, possibly milder and the NK cells were activated through concomitant adminis-
tration of interleukin 2 (IL-2). Miller et al reported for the first time the use of IL-2 stimulated
haploidentical NK cells in a cohort of patients with poor prognosis AML in whom high dose
cyclophosphamide and fludarabine was used for conditioning [6]. Two patients experienced
grade 4 neutropenia and 2 others developed grade 3 neutropenia following cyclophosphamide.
In a similar study by the same group in a cohort of patients with recurrent ovarian and breast
cancer, 4/5 patients developed grade 4 neutropenia beyond day+28 when 2Gy of TBI was
added in a high dose of cyclophosphamide and fludarabine regimen [8]. The median time to
neutrophil recovery in the TBI cohort was 32 days as compared to 15 days in the non TBI one
(p = 0.014).
Nevertheless the intensity of the regimen might not be the only explanation for the pro-
longed cytopenias. The NK cell product might play a significant role especially in patients
where prolonged donor NK cell chimerism can be demonstrated. This has also been suggested
by both studies fromMiller et al and Rubnitz et al [9]. Miller et al [6] treated a patient with
relapsed AML post nonmyeloablative double cord transplantation with cyclophosphamide/flu-
darabine haploidentical NK cells from his sister about 100 days after cord blood transplanta-
tion. Full and sustained haploidentical NK-cell engraftment was shown at day +14. As the
patient remained neutropenic for 3 weeks GCSF was started and the patient eventually
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achieved absolute neutrophil count>0.5x109/l six weeks after the NK cell infusion. By that
time there was no evidence of cells from the haploidentical donor. In the study by Rubnitz et al
[9], all patients but one achieved neutrophil and platelet engraftment by day +21. The only pa-
tient with delayed recovery had prolonged NK engraftment with 2% donor NK cells at day
+189. This patient had delayed neutrophil and platelet recovery, as well as lymphopenia with
an absolute lymphocyte count less than 0.5x109/L until day +189. At day +261 this patient had
no detectable donor NK cells and had complete hemopoietic recovery.
Our in vitro assays of tumor-primed NK cell alloreactivity to normal hemopoieitic stem
cells in the preclinical phase and during this trial showed no lysis or suppression of normal
CD34+ bone marrow cells. However, murine experiments have shown NK activity against nor-
mal allogeneic bone marrow is enhanced by low dose TBI which may explain both our results
and those of the Minnesota group.
Although this study was aiming to assess toxicity of the haploidentical NK cell product in a
cohort of patients with high risk AML, our results indicate that this approach is associated with
engraftment; tracking of donor NK cells to the bone marrow and promising clinical outcome.
The presence of donor NK cells in the bone marrow whilst undetectable in the peripheral
blood is in line with a recent report of rapid marginalisation of donor NK from peripheral
blood after administration followed by reappearance in the periphery days later [12]. We did
not study the acute dynamics of NK cell engraftment but it is certain that adoptively transferred
NK cells can leave the periphery and, as we observed, can marginalise to the bone marrow;
presumably in response to the presence of tumor. The fact that only three patients could be
monitored for donor NK chimerism prevents any analysis of the presence or level of NK en-
graftment with respect to outcome although Miller’s group in Minnesota has observed a
threshold of donor NK engraftment which is associated with clinical response (Miller—person-
al communication). Our report here of high frequency of donor NK cells in a bone marrow as-
pirate whilst undetectable in peripheral blood suggests that chimerism analyses will need to be
more thorough than simple peripheral blood monitoring.
It is a common observation in patients with AML who achieve serial remissions after
courses of chemotherapy that each subsequent remission is always shorter than its immediate
predecessor. Three of our patients experienced longer remissions and one patient who had
Fig 7. Haploidentical tumor-primed NK cells do not suppress hematopoietic progenitor cells (HPC) in
vitro. A—Tumor primed NK cells co-incubated with haploidentical CD34 selected HPC did not suppress
BFU-E (white bars), CFU-GM (gray bars) or GFU-GEMM (black bars). B—T cells from the same
haploidentical donor substantially inhibited growth of donor CFU-GM (gray bars) C—In vivo donor T cell
(Open triangles) and NK (Open Squares) cell chimerism.
doi:10.1371/journal.pone.0123416.g007
Table 5. HLA-KIRmismatch.
PATIENT Donor Donor Class I m/m Predicted KIR m/m
CTI 01 Daughter A 0205 B 4901 C 0701 No M/M
CTI 03 Daughter A 2402 B 3501 C 0401 M/M 2DL1
Host vs Donor
CTI 04 Brother A 2601 B 1401 C 0802 M/M 3DL1
Donor vs Host
CTI 07 Son A 0301 B 3501 C 0401 No M/M
CTI 09 Daughter A 2601 B 3801 C 1203 No M/M
CTI 08 Son A 0101 B 0801 C 0701 No M/M
CTI 11 Son A 2901 B 4403 C 1601 No M/M
doi:10.1371/journal.pone.0123416.t005
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never previously achieved CR and was in partial remission prior to the NK cell infusion,
achieved complete morphological remission with normal peripheral counts for 8 months (Fig
4). Considering the fact that this was a cohort of patients with high risk disease including mul-
tiple relapses and even failed previous autologous or allogeneic transplants, additional studies
will be required to assess efficacy in patients with less adverse prognostic features.
One of the most remarkable observations was the sustained engraftment of haplomis-
matched donor NK cells in Patient 03 after a second infusion without further cytoreductive
conditioning. This implies that the patient had developed tolerance to the mismatched alleles
after the first infusion, raising the intriguing possibility that the initial tumor-primed NK cells
may have deleted the host alloreactive T cell clones by a “veto” phenomenon. This has been re-
ported before in murine models but never in a human transplant setting [13]. It raises the pos-
sibility of using multiple courses of tumor-primed NK cell therapy to control AML in patients
unable to tolerate conventional allogeneic HSCT or who lack a suitable donor.
The study suffered several failures in GCP compliance, mostly due to the complexity of de-
livery of an allogeneic cell therapy as an advanced therapy investigational medicinal product
(ATIMP) in an academic setting. Anecdotally, these failures are not uncommon in such inves-
tigator-led cell therapy trials and many were due to inadequacies in the trial protocol despite
the fact that it had been externally peer-reviewed by the funding body’s clinical trials commit-
tee and the UKMedicines and Healthcare products Regulatory Agency (MHRA) before ap-
proval. The allogeneic product required identification, screening and consent of the related NK
donor prior to apheresis, product manufacture, patient conditioning and finally treatment. In
this group of patients with advanced or poor risk AML the likelihood of disease relapse during
this period was underestimated. Furthermore, the relapse or death of patients during this pre-
treatment period was not considered to be a “trial related” event by the investigators and yet,
according to the protocol, any relapses or deaths during this period should have been reported
as a serious adverse event on trial. The protocol could have been written to define more clearly
the required reporting period for Severe Adverse Events to exclude events prior to commence-
ment of the conditioning chemotherapy. However, the question of reporting “all deaths on
trial” remains a significant problem in studies such as this. Patients with advanced and aggres-
sive disease are at high risk of relapsing and dying prior to treatment with the investigational
drug. One might argue that enrolment should be at the last minute such as, in this case, the
commencement of the conditioning chemotherapy. This would have maximised the chance of
enrolling a full complement of patients who actually received the trial drug and were informa-
tive with regard to toxicity and overall safety. However, the fact that the investigational drug is
patient specific a requires a clinical intervention to procure the starting material approximately
15 days prior to starting conditioning chemotherapy prevents this under current interpretation
of GCP. This trial highlights the need to hold discussions with the GCP regulator and the spon-
sor over GCP compliance during the trial design to prevent complications later.
Early phase trials of ATIMPs are often restricted to the higher risk patient groups who have
failed all lines of conventional treatment. In this trial the number of disease-stage related ad-
verse events, whilst expected, was not predicted in the protocol and thus not listed in the chart
of expected adverse events. This highlights the requirement to be very comprehensive in listing
the adverse events which are likely to occur in the patient group being studied if they were to
remain untreated or to receive best available conventional care. This reduces the number of ad-
verse events requiring expedited reporting and makes GCP compliance considerably less
onerous.
It must also be appreciated that recruitment to ATIMP clinical trials is often slower than
predicted; this is a very common theme across all fields of cell therapy. It is difficult to justify a
clinical trials team employed solely to support a single trial and thus retraining new staff
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throughout the trial and recording their training and competencies in the trial records is essen-
tial. These trials need to be conducted within experienced clinical research facilities with appro-
priate quality management systems in place.
A final consideration regarding trials of ATIMPs is an ethical consideration unique to such
drugs. Unlike any conventional pharmaceutical, patient-specific cell therapy and tissue engi-
neered ATIMPs consist of autologous or allogeneic donor cells as a critical starting material.
The procurement of these cells is invariably associated with a clinical procedure which has put
the patient or a donor at some degree of risk or, at least, discomfort. Given the paucity of truly
informative pre-clinical data on most ATIMPs it is often ethically difficult to justify discarding
a product and excluding a patient on the basis of late failure to meet inclusion criteria or some
other aspect of a protocol. In our case, the trial was suspended after the seventh patient had re-
ceived treatment in order to address the non-compliances with GCP discussed above. Howev-
er, an eighth patient product had been manufactured and a decision was made to release this
for treatment on a compassionate basis but to exclude the patient from the trial dataset and the
outcome results are excluded from the analysis presented here. Investigators need to consider
how to deal with these situations before completing the trial protocol and to ensure that pa-
tients or donors who are contributing starting materials are fully aware that the product may
not be used in certain circumstances.
In conclusion, this is the first report of adoptive immunotherapy with activated NK cells in
the absence of exogenous in vitro and in vivo IL-2. Furthermore it is the first report of the use
of activated NK cells which were cryopreserved prior to administration, quality controlled and
released to the patient as a cellular medicine without subsequent, additional activation. This is
the first study to demonstrate safety of tumor-primed NK cells in a cohort of patients with high
risk AML; albeit with failures in contemporaneous GCP compliance which required retrospec-
tive review and reporting. The NK cells can survive in vivo even without immunosuppression
and exert a potent anti-leukemia effect. In order to assess further the efficacy in adult patients
with AML in CR1 a multicenter study is now under IND at multiple US sites.
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